The DIRECCT study is a multi-phase, living examination of clinical trial results dissemination throughout the COVID-19 pandemic. Currently the data for Phase 1 are available. Phase 1 of the project examined trials completed during the first six months of the pandemic (i.e., through 30 June 2020). Data were collected using a combination of automated and manual strategies; automated searches were performed on 30 June 2020, and manual searches were performed between 21 October 2020 and 18 January 2021. The data for the study are split into three datatables: `trials`, `registrations`, and `results`. The three datatables can be treated as relational and joined on the `id` column. Variables are documented in `data-dictionary`. Data sources for `trials` and `registrations` include the International Clinical Trials Registry Platform (ICTRP) list of registered COVID-19 studies, and individual clinical trial registries; data from these sources were curated and cleaned through the COVID-19 TrialsTracker project (https://covid19.trialstracker.net/). Some of the trial data included in the dataset are provisional and have not been systematically quality controlled (e.g., data on interventions); this is noted in the data dictionary when applicable. Data sources for `results` include information on trial results located from our automated and manual searches in the COVID-19 Open Research Dataset (CORD-19), PubMed, EuropePMC, Google Scholar, Google, and registries. Additional information on the project is available at the project's OSF page: https://doi.org/10.17605/osf.io/5f8j2.

Phase 1 of DIRECCT is part of the CEOsys (COVID-19 Evidence Ecosystem) project funded within the Network of University Medicine (Nationales Forschungsnetzwerk der Universitätsmedizin - NUM) by the Federal Ministry of Education and Research of Germany (Bundesministerium für Bildung und Forschung - BMBF). FKZ: 01KX2021